35 related articles for article (PubMed ID: 9185704)
1. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
Honeychurch J; Cruise A; Tutt AL; Glennie MJ
Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
[TBL] [Abstract][Full Text] [Related]
2. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
3. The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotype antibodies.
Ong GL; Marria V; Mattes MJ
Cancer Immunol Immunother; 1994 Nov; 39(5):325-31. PubMed ID: 7987864
[TBL] [Abstract][Full Text] [Related]
4. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation.
Taya M; Haimovich J
Cancer Immunol Immunother; 1991; 34(1):43-8. PubMed ID: 1760810
[TBL] [Abstract][Full Text] [Related]
6. Effects of anti-idiotype vaccine on tumour growth and on production of soluble factors modulating cell-mediated immunity in vitro.
Greer JM; Halliday WJ
Cancer Immunol Immunother; 1991; 33(3):171-6. PubMed ID: 1710543
[TBL] [Abstract][Full Text] [Related]
7. Targeting proteins with bivalent glues.
Crunkhorn S
Nat Rev Drug Discov; 2024 Apr; 23(4):253. PubMed ID: 38448669
[No Abstract] [Full Text] [Related]
8. Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.
Bodet-Milin C; Ferrer L; Pallardy A; Eugène T; Rauscher A; Alain Faivre-Chauvet ; Barbet J; Kraeber-Bodéré F
Front Oncol; 2013; 3():177. PubMed ID: 23875170
[TBL] [Abstract][Full Text] [Related]
9. "Peptabody": a new type of high avidity binding protein.
Terskikh AV; Le Doussal JM; Crameri R; Fisch I; Mach JP; Kajava AV
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1663-8. PubMed ID: 9050835
[TBL] [Abstract][Full Text] [Related]
10. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.
Le Doussal JM; Barbet J; Delaage M
Int J Cancer Suppl; 1992; 7():58-62. PubMed ID: 1428406
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional antibodies for radioimmunotherapy.
Chatal JF; Faivre-Chauvet A; Bardies M; Peltier P; Gautherot E; Barbet J
Hybridoma; 1995 Apr; 14(2):125-8. PubMed ID: 7590767
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
[TBL] [Abstract][Full Text] [Related]
13. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
14. Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells.
Manetti C; Le Doussal JM; Rouvier E; Gruaz-Guyon A; Barbet J
Int J Cancer; 1995 Oct; 63(2):250-6. PubMed ID: 7591213
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
